Početna stranicaP8A • SGX
add
Cordlife Group Ltd
Preth. zaklj. cijena
0,18 $
Dnevni raspon
0,18 $ - 0,18 $
Godišnji raspon
0,12 $ - 0,47 $
Tržišna kapitalizacija
45,52 mil. SGD
Prosječna količina
66,40 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
SGX
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (SGD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 4,60 mil. | −67,54 % |
Operativni troškovi | 8,59 mil. | −6,80 % |
Neto dohodak | −6,18 mil. | −655,33 % |
Neto profitabilnost | −134,45 | −1.810,56 % |
Zarada po dionici | — | — |
EBITDA | −6,84 mil. | −615,37 % |
Efektivna porezna stopa | 8,73 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (SGD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 59,54 mil. | −15,89 % |
Ukupna imovina | 224,31 mil. | −4,16 % |
Ukupne obveze | 101,27 mil. | 3,31 % |
Ukupni kapital | 123,03 mil. | — |
Dionice u optjecaju | 256,31 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,36 | — |
Povrat imovine | −8,79 % | — |
Povrat kapitala | −15,66 % | — |
Tok novca
Neto promjena novca
| (SGD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −6,18 mil. | −655,33 % |
Gotovina od poslovanja | −2,95 mil. | −192,71 % |
Gotovina iz ulaganja | 2,90 mil. | 258,76 % |
Gotovina iz financiranja | −549,50 tis. | −19,59 % |
Neto promjena novca | −498,00 tis. | −153,06 % |
Slobodan tok novca | −4,65 mil. | −1.473,26 % |
Više
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
Glavni izvršni direktor
Osnovano
2. svi 2001.
Web-lokacija
Zaposlenici
111
